Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
A phase 2/3 trial of Cisplatin, Gemcitabine and Carboplatin in bladder & urothelial cancer, run by Bristol-Myers Squibb, now recruiting.
Overview
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy is a phase 2/3 interventional study registered as NCT07106762 by Bristol-Myers Squibb, with 470 participants planned, started 2025-09-30 and due to reach its primary completion in 2029-01-26. Interventions recorded: Iza-bren, Cisplatin, Gemcitabine and Carboplatin.
Similar pages
not linked directly; found by shared links- Trial9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
Shares Gemcitabine, Bristol Myers Squibb, Cisplatin, Carboplatin and the tag pipeline.
- TrialStudy of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialA Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.